Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 11 - 12 symbols : NVO save search
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | News | $126.79 1.22% 340K
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
LLY | News | $735.9 0.63% 180K
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
ALNY | $147.93 1.47% 13K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
preclinical collaboration research license pre-clinical
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | News | $126.79 1.22% 340K
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
LLY | News | $735.9 0.63% 180K
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
ALNY | $147.93 1.47% 13K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
disease liver disease phase 1 liver trial
Ozempic® 2.0 mg recommended for approval for the treatment of type 2 diabetes by the European Medicines Agency
Published: 2021-11-12 (Crawled : 11:00) - globenewswire.com
NVO | News | $126.79 1.22% 340K
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
diabetes treatment europe approval
Gainers vs Losers
| 81% | 19% |
Top 10 Gainers
MTTR | News M | $4.625 165.81% 5.5M
|
AGBA | $2.615 109.2% 14M
|
Finance
EDBL | News | $7.37 96.01% 650K
|
PALI | $7.64 54.97% 14M
|
Manufacturing
OPRT | News | $3.19 41.78% 3M
|
Finance
PEGY | $0.0629 37.34% 110M
|
Manufacturing
MLEC | $1.87 33.57% 1.6M
|
n/a
ATGL | $3.66 27.97% 150K
|
SMFL | $5.35 22.99% 11M
|
Manufacturing
KULR | $0.5446 22.0% 6.8M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.